{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:20:05Z","timestamp":1790572805558,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eururo.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T22:29:16Z","timestamp":1661207356000},"page":"602-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1016","volume":"82","author":[{"given":"Khyati","family":"Meghani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Folgosa","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabah S.","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.08.004_b0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.08.004_b0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.08.004_b0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1590\/S1677-55382009000600002","article-title":"Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review","volume":"35","author":"Chade","year":"2009","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2022.08.004_b0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.08.004_b0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.euo.2021.05.008","article-title":"Urologists, you'll never walk alone! How novel immunotherapy and modern imaging may change the management of non-muscle-invasive bladder cancer","volume":"5","author":"Giannarini","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2022.08.004_b0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/JU.0000000000001576","article-title":"Intravesical anti-PD-1 immune checkpoint inhibition treats urothelial bladder cancer in a mouse model","volume":"205","author":"Kirschner","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.08.004_b0035","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1084\/jem.20181003","article-title":"Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment","volume":"215","author":"Wong","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.eururo.2022.08.004_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00941903","article-title":"Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer","volume":"25","author":"de Boer","year":"1997","journal-title":"Urol Res"},{"key":"10.1016\/j.eururo.2022.08.004_b0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.08.004_b0050","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2022.08.004_b0055","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.21037\/tau-2019-mibc-12","article-title":"Update on bladder cancer molecular subtypes","volume":"9","author":"Fong","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2022.08.004_b0060","doi-asserted-by":"crossref","first-page":"e8757","DOI":"10.1097\/MD.0000000000008757","article-title":"New onset of myasthenia gravis after intravesical bacillus Calmette-Guerin: a case report and literature review","volume":"96","author":"Takizawa","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eururo.2022.08.004_b0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","article-title":"Myasthenia gravis induced by immune checkpoint inhibitors","volume":"42","author":"Becquart","year":"2019","journal-title":"J Immunother"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822025532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822025532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:12:08Z","timestamp":1759583528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822025532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0302283822025532"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.08.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Gu\u00e9rin","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}